chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report as received from a pharmacist refers to an unspecified number of patients of unknown age and gender. The patients' concurrent conditions, medical history and concomitant medications were not provided. On an unknown date, the patients were vaccinated with doses of ZOSTAVAX vial (19400 plaque-forming unit (PFU, dose, route of administration, lot# and expiration date were not reported) and on an unknown date, the patients were vaccinated with doses of PNEUMOVAX 23 (dose, route of administration, lot # and expiration date were not reported). It was reported that doses of ZOSTAVAX and PNEUMOVAX 23 were administered 4 weeks apart. On an unknown date, the patients experienced injection site reactions. The pharmacist noticed that more patients (unspecified number) experienced injection site reactions when ZOSTAVAXC and PNEUMOVAX 23 were administered concomitantly (captured in MARRS# 1604USA000233), than wen ZOSTAVAX and PNEUMOVAX 23 were administered 4 weeks apart. The outcome of injection site reactions was not reported. Causality assessment was not provided. This is one of two reports received from the same reporter. Additional information has been requested.
This case was reported by a healthcare professional via a sales representative and described the occurrence of nonspecific reaction in a subject of unspecified age and gender who was vaccinated with DTP (A or W not known) vaccine (manufacturer unspecified). On an unspecified date the subject received unspecified dose of DTP (A or W not known) (unknown). At an unspecified time after vaccination with DTP (A or W not known), the subject experienced nonspecific reaction. At the time of reporting the outcome of the event was unspecified. This event was reported because the reporter would like to give BOOSTRIX to the subject who experienced an unspecified moderate reaction to a DTaP or DTwP vaccine approximately 10 years ago. Event reported as above.
Patient came to pharmacy on 10/22/2018 with redness and swelling at injection site. Advised patient that this could happen with flu vaccine before vaccination and again at time of occurrence. Advised patient to apply cold compress and take OTC analgesic.
Intense itching on neck arms and torso, 24 hours later around 5:00 PM, I started itching again but with hives. I called my doctor and she prescribed Betamethasone DP 0.05% she also recommended to take Benadryl at night, and Claritin during the day.
Patient received Hepatitis A  and Menveo on Feb 3rd as part of annual check. Patient had received these vaccines before.  Patient left the clinic in stable condition about 15  minutes after receiving the vaccine.  Patient was anxious while receiving vaccines.  Next day mother called clinic and informed us that patient went to ER after leaving the clinic as she noticed that patient appeared flushed, reports shortness of breath and some possible tongue swelling. Patient was seen in ER and diagnosed  with Allergic reaction, Angioedema and treated with steroids and anti histamine.
Eye itch; This spontaneous case was reported by a consumer and describes the occurrence of EYE PRURITUS (Eye itch) in a 91-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Jan-2021, the patient experienced EYE PRURITUS (Eye itch). At the time of the report, EYE PRURITUS (Eye itch) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication was not reported. Treatment medication was not reported.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of this event, a causal relationship cannot be excluded.
Diarrhea 9PM on 11/9/2014 through 12PM on 11/12/2014. Fever on 11/9/2014 off and on through 11/11/2014. Severe diaper rash from diarrhea 11/10/14 - 11/13/14 (continuing). Chicken pox rash (5 pox lesions), first one appearing on 11/10/14, the rest appearing Nov 11-12, 2014. Generalized sleeping difficulty, crankiness, etc.
His mother reported that he began to have tics in his arm in 1998. He has reportedly been seen "numerous" times by physicians. A neurologist performed an unspecified magnetic resonance imaging MRI study; results of this study were not provided. The mother reported that the neurologist made a diagnosis of Tourette's syndrome. The vaccinee "now has severe tics all over his body, and his eyes roll back into his head." Treatment of the Tourette's syndrome was not specified.
Sweating/clammy, vomiting, felt faint, dizziness. Blood pressures 93/56 (pulse 71), 99/58 (pulse 92). O2 sats 100%.
My Dad complained about dizziness, feeling unbearably cold and weak. There was also shaking of the extremities.
placing two and a half boxes of the Shingrix vaccines/ by mistake/Shingrix placed in the freezer; This case was reported by a physician via call center representative and described the occurrence of incorrect storage of drug in a patient who received Herpes zoster (Shingrix) (batch number E9C7K, expiry date 14th October 2022) and (batch number 393C7, expiry date 25th October 2022) for prophylaxis.   On 20th June 2021, the patient received Shingrix. On 20th June 2021, the dose was an unknown dose. On an unknown date, unknown after receiving Shingrix, the patient experienced incorrect storage of drug. On an unknown date, the outcome of the incorrect storage of drug was unknown.  Additional details were provided as follows: The age at vaccination was not reported. The reporter stated that, placing two and a half boxes of the Shingrix vaccines by mistake. No further events were reported. The reporter consented to follow up.
Headache, Myalgia, night sweats, fatigue Narrative: Missed one day of work due to night sweats, headache, body aches, fatigue.
The patient came in to the pharmacy 2 days after receiving the vaccination. She stated that the reaction began the day after the injection, but it had progressed to its current state earlier in the same day that she came in. She complained of soreness and a "heavy" feeling in her arm. She showed me her arm and it was noticeably red and swollen. The redness was approximately 5 inches in length. The patient also stated that the site was hot to the touch. I suggested that she be seen at a nearby urgent care clinic so they could assess the level of the issue. The patient was receptive to the advice and was polite in all of our interactions.
Had continuing dizziness, poor balance, exacerbation of partial Seizure Symptoms, developed Neuropathy in her hands and feet, then strange sensations up arms and legs and fingertips. Tingling in scalp.
5 - 10 minutes after Pt received 2nd VARIVAX, she started to c/o of sore throat, PF; bilat. wheezing, no swelling of lips; improved after Epinephrine 0,3 ml.
Severe headache, has continued intermittently until present. Strange menstrual flow, was very heavy, with clotting, unusual per patient
This spontaneous case reported by a consumer, describes the occurrence of feeling abnormal and vaccination complication (experienced unusual and concerning symptoms) in a 19-year-old male patient who received mRNA-1273 (Moderna COVID-19 vaccine, batch/lot# unknown) for COVID-19 immunization. No medical history reported. On Jan 4, 2022, patient received the third dose of mRNA-1273 (Moderna COVID-19 vaccine), unknown route; 1 dosage form. On an unknown date, patient experienced feeling abnormal and vaccination complication (experienced unusual and concerning symptoms). At the time of the report, feeling abnormal and vaccination complication (experienced unusual and concerning symptoms): resolving. Healthy male, no underlying health issues. Symptoms eased. No concomitant medication or treatment information reported.
Information has been received from a registered nurse regarding a patient of an unknown age and gender. On 17-JAN-2013 at 07:45, ZOSTAVAX lot # H019999 was exposed to-14C for an estimated total time out of range of 14-25 hours. On 30-JAN-2013 at 18:00, ZOSTAVAX lot # H019999 was exposed to -14C for an estimated total time out of range of 10.5 hours. On 08-FEB-2013, the patient was vaccinated with an out of range dose of ZOSTAVAX (dose and route administration were not provided) (Lot number H019999). No adverse experience had been reported. This is one of 182 reports from the same source. Additional information has been requested.
Patient c/o dizziness at 1:12pm.  He was laid down in a supine position. Encouraged slow deep breaths, elevated his legs. BP=140/82, HR=112, RR=20. Offered apple juice, candy, and water. @1:20pm, BP=144/84, HR=82, RR=16. Patient denies feeling dizzy any more. Patient was d/c at 1:28pm with no trauma or falls while on site.
I began noticing red spots on both breasts, then chest, stomach, back, and right arm have began to increase in burning sensation with no discoloration. It feels like I have a rash but no redness or swelling.
chest pains; fever over a 100°F; AFib; diabetic; COPD; stomach issues; This is a spontaneous report from a contactable consumer (patient). A 74-years-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, Solution for injection, lot number and expiry date not reported), via an unspecified route of administration on 25Jan2021 at a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. Patient received first dose on 25Jan2021 and experienced health issues in Jan2021 as AFib, diabetic, COPD, stomach issues, and reported to "have a lot of issues". The primary doctor thought it's better for her to get the dose than get COVID-19. Patient also reported that about 20 minutes after the first dose on 25Jan2021, patient had chest pains, from one side clear across the other side and took a Nitro, and patient had fever over a 100 degree F for 24 hours. The outcome of the events was unknown.   Information on about lot/batch number has been requested.
Pt recv vax on 1/26/98; post vax in 1/98 pt exp vax site rx of redness & soreness
1. severe pain to left side from collar bone to finger tips.  2. swollen, painful 3 cm cyst or  lymph node on left collar bone.
This spontaneous report as received from the healthcare worker refers to multiple unspecified number of patients of unspecified age and gender. Medical history and concurrent conditions were not reported. On an unknown date, the patients were vaccinated with improperly stored PNEUMOVAX 23 (lot number: 1022795 and 1008664: expiry date: 05-NOV-2016 and 03-NOV-2016 respectively) (dose, frequency and route of administration was not reported). No concomitant medications were reported. No adverse events were experienced. The outcome of the reported events was unknown. No product quality complaint (PQC) was filed. This is one of 4 reports from the same reporter. Additional information has been requested.
Information has been received from a registered nurse concerning a 27 year old female who in 1981 was vaccinated with a first dose of MMR II, in 1997 was vaccinated with a second dose of MMR II and in 2006 was vaccinated with a third dose of MMR II. The patient has negative measles titer even after receiving 3 doses of MMR II. The patient has positive titer for rubella and mumps. No adverse effect reported. Follow up information was received. It was reported 28 year old (previously reported as 27 year old) female who was not a smoker was vaccinated with a first, second and third dose of MMR II on 10-SEP-1981, 20-JUN-1997 and 11-AUG-2006 respectively. The patient's rubeola titer was 0.98 (equiv. result). No further information was available.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 70-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 13Mar2021 as dose 1, single (Lot number: EN6199), in left arm, on 03Apr2021 as dose 2, single (Lot number: EW0150), in left arm, on 20Oct2021 as dose 3 (booster), single (Lot number: FH0820), in left arm and on 31Mar2022 as dose 4 (booster), single (Lot number: FK9894) at the age of 69 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Atherosclorotic" (unspecified if ongoing), notes: Atherosclorotic; "known allergies: Sulfa drugs" (unspecified if ongoing), notes: known allergies: Sulfa drugs; "quarternary salts" (unspecified if ongoing), notes: Known allergies: quarternary salts. The patient's concomitant medications were not reported. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Aug2022, outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of vaccination failure, covid-19 included treatment with Paxlovid from 13Aug2022 to 18Aug2022.  Clinical course: The patient was not taking any other medications/products within 2 weeks of starting COVID-19 treatment. Rebounded symptoms -congestion, cough, sore throat, but no fever, within 3 days of initial symptom abatement  No follow-up attempts are possible. No further information is expected.
Parents noted onset of L/arm pain, swelling & redness 1-2 days after vax. Seen by MD, 12/10/99, erythema over approx 1/3 of lateral surface of upper arm, 1cm diameter area of induration at injection site & moderate swelling at area of
3:00 AM Sore throat, headache. 8:00 AM headache, dizzy.  9:30 AM Fainted, Temp 99.8 BP 100/60 Pulse 116/122.
patient received a fourth dose of HepB (Engerix-B).; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 18-year-old female patient who received HBV (Engerix B) (batch number A9349, expiry date 19-APR-2024) for prophylaxis.   On 02-OCT-2023, the patient received the 4th dose of Engerix B. On 02-OCT-2023, an unknown time after receiving Engerix B, the patient experienced extra dose administered (Verbatim: patient received a fourth dose of HepB (Engerix-B).). The outcome of the extra dose administered was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK receipt date: 13-OCT-2023 A pharmacist reported that a patient received a fourth dose of Hepatitis B (Engerix-B), which led to extra dose administered. The health care professional (HCP) asked for any side effects. The reporter consented to follow up.
Pt complained of high fever. Pain in arms and legs. Atrial fibrillation went to ER. Weakness.
This case was reported by a nurse via call center representative and described the occurrence of vomiting in a female patient who received BEXSERO (batch number 16B701, expiry date 1st February 2019). On 27th September 2017, the patient received BEXSERO. On 27th September 2017, less than a day after receiving BEXSERO, the patient experienced vomiting, headache, muscle pain, fever chills, mobility decreased, sweating, injection site mass and chills. On an unknown date, the outcome of the vomiting, mobility decreased and sweating were recovering/resolving and the outcome of the headache, muscle pain, fever chills and chills were recovered/resolved and the outcome of the injection site mass was not recovered/not resolved. It was unknown if the reporter considered the vomiting, headache, muscle pain, fever chills, mobility decreased, sweating, injection site mass and chills to be related to BEXSERO. Additional details were provided as follows: This case was reported by licensed practical nurse. The age at vaccination of patient was not reported. The patient experienced multiple adverse reactions including vomiting for 12 hours, sweating on the palms of hands and bottoms of feet, a knot formed on the arm at location of injection and trouble moving arm. The knot at location of injection still remains 5 days post-vaccination.
Vaccine recipient developed headache, dizziness, fogginess, feeling flushed, cold sweats and a weird tingling sensation hours after receiving the vaccine. He also noted developing mental confusion. He did not have to go to the ED and went home for the rest of the day. For 1.5 days, he was home resting. On a follow-up call on 1/11/2021, vaccine recipient reported feeling better. Pfizer-BioNTech COVID- 19 Vaccine EUA.
Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021; Vaccine received post its 30 days Expiry date; This spontaneous case was reported by an emergency medical technician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine received post its 30 days Expiry date) and PRODUCT STORAGE ERROR (Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021) in a 90-year-old male patient who received mRNA-1273 (Spikevax) (batch no. 066H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 10-Feb-2022 at 4:33 PM, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) .5 milliliter. On 10-Feb-2022 at 4:33 PM, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine received post its 30 days Expiry date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine received post its 30 days Expiry date) and PRODUCT STORAGE ERROR (Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication of the patient was not reported.  Vaccine administration time was given as 10-Feb-2022 16:33:52.  No treatment information was provided by the reporter.   This case was linked to MOD-2022-542869 (Patient Link).
She got the vaccine, went home and about 45 minutes she got the vaccine she started having serious chest pains and her throat started to feel tight.  She can't drive due to the brain aneurysm so she laid down.  She had pain at the injection site and throat tightness for about 3 days, and she just generally did not feel good for about 3 days.  The chest pain lasted for about an hour.  She did not take anything for her symptoms.   On the 3rd day she felt better.  She is now afraid to get the 2nd vaccine due to her reaction.  She tried to call Pfizer to report this and ask for their advice.   She has contacted her allergist who is going to notify the college about the 2nd vaccine and they may send her up there.
patient did not get the full dose; syringe malfunction; A spontaneous report was received from a healthcare professional concerning a patient, of unknown age and gender, who was administered Moderna's COVID-19 vaccine but due to syringe malfunction/ PT: device connection issue, the patient did not get the full dose/ PT: underdose.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On an unknown date, prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (Batch/Lot number: not provided) intramuscularly for prophylaxis of Covid-19 infection.  It was reported that due to a syringe malfunction that day, the patient didn't get the full dose.  No treatment information was provided.  Action taken with the second dose of mRNA-1273 in response to the event was not reported.  The events, syringe malfunction and patient did not get the full dose, were considered resolved.; Reporter's Comments: This report refers to a case of Vaccine underdose and Device connection issue for mRNA-1273 (Batch/Lot number: not provided) with no associated AEs.
OUT SICK FOR TWO DAYS; ACHES; CHILLS; FEVER; This spontaneous report received from a patient via a company representative concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine  (suspension for injection, route of admin not reported, batch number: Unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported.  On an unspecified date, the subject experienced out sick for two days, aches, chills, and fever. The action taken with covid-19 vaccine  was not applicable. The patient recovered from out sick for two days, aches, chills, and fever. This report was non-serious.
Vaccine used past the 12 hour window of use once bottle was punctured. Stored in refrigerator entire time of use and cleaned between use with alcohol. Contacted patient and no adverse reaction reported.
Chills; Headache; Bodyache; This is a spontaneous case is received from a contactable consumer (patient). A 25-years-old pregnant female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Batch/Lot Number: EL3247), via an unspecified route of administration, administered in arm right on 10Feb2021 11:15 as single dose for covid-19 immunisation. The patient medical history and concomitant medications were not reported. Historical vaccine included bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE) on 20Jan2021. The patient experienced chills, headache and bodyache on 11Feb2021. The outcome of the events was recovering.
Swollen lymph node in neck on the left side causing soreness in throat and left ear. Soreness is worse when laying down. Also experience breast pain in left breast and periodic burning sensation in left arm at vaccine site. Symptoms continue over a month after vaccine was administered. I am pregnant and was pregnant at the time of vaccination. Estimated due date is November 7th 2021.
Rash on my left hand It has kind of spread over the back of my left hand; This is a spontaneous report received from a non-contactable consumer or other non hcp. A female patient of an unspecified age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Batch/Lot Number: EW0167), via an unspecified route of administration on an unspecified date as 1st dose, single dose for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient experienced rash on my left hand it has kind of spread over the back of my left hand on an unspecified date. The events were assessed as non-serious. Reporter stated, patient wants to check what level of protection if she don't get the second dose this June 5 which was this Saturday since she was experiencing rashes after getting the first dose on May 15. Consumer stated, about maybe four days after she got the shot or maybe 5 days, developed a rash on my left hand. She thought maybe something, ants or something they had bitten me or something, just didn't knew why because she didn't realize a rash could be a side effect from the Pfizer shot. But anyway it has kind of spread over the back of my left hand and about 4 or 5 or about 3 or 4 days after that, she noticed the same rash coming on my right hand as well. For about the last 2 weeks, it has been kind of progressive and then today for the first time, she noticed some rash around the lower part of neck. Further probing could not be done as consumer was unwilling to further answer the questions. Hence, other details are unknown and limited information was available over the call. The outcome of the events was reported as unknown.    Follow-up attempts are possible. further information is expected.